Open AccessMacrolide-Resistant Mycoplasma pneumoniae in the United States as Determined from a National Surveillance Program
Author(s) -
Ken B. Waites,
Amy E. Ratliff,
Donna M. Crabb,
Li Xiao,
Xiaoming Qin,
Rangaraj Selvarangan,
YiWei Tang,
Xiaotian Zheng,
Jennifer Dien Bard,
Tao Hong,
Mark N. Prichard,
Edward G. Brooks,
Steve Dallas,
Lynn B. Duffy,
Emily Mixon,
Karen B. Fowler,
T. Prescott Atkinson
Publication year - 2019
Publication title -
journal of clinical microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.349
H-Index - 255
eISSN - 1070-633X
pISSN - 0095-1137
DOI - 10.1128/jcm.00968-19
Subject(s) - mycoplasma pneumoniae , 23s ribosomal rna , incidence (geometry) , medicine , azithromycin , mycoplasma , microbiology and biotechnology , biology , pneumonia , antibiotics , ribosome , rna , biochemistry , physics , optics , gene
There are sparse data to indicate the extent that macrolide-resistantMycoplasma pneumoniae (MRMp) occurs in the United States or its clinical significance. Between 2015 and 2018, hospitals in 8 states collected and stored respiratory specimens that tested positive forM. pneumoniae and sent them to the University of Alabama at Birmingham, where real-time PCR was performed for detection of 23S rRNA mutations known to confer macrolide resistance. MRMp was detected in 27 of 360 specimens (7.5%).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom